According to the survival analysis results from Kaplan‐Meier plotter (http://kmplot.com/analysis/), the overall survival (OS) signature (high risk vs. low risk) of TXN2 (Affymetrix ID: 209078_s_at) presents high‐TXN2‐expression patients’ overall survival time is shorter than that of low‐expression NSCLC patients (hazard ratio [HR] 1.19; P = .0076), especially for LUAD (HR = 1.76, P = 2.7e‐6) (Figure 4D,E). This evidence concerns the gene TXN2 and non-small cell lung carcinoma.